{
  "meta": {
    "data_length": 1,
    "message": "Indication id ind:hc.revlimid:0 retrieved successfully",
    "request_url": "http://api.moalmanac.org/indications?indication_id=ind%3Ahc.revlimid%3A0",
    "status": "success",
    "status_code": 200,
    "timestamp_elapsed": 0.003843,
    "timestamp_received": "2026-04-06T14:48:50.486406+00:00Z",
    "timestamp_returned": "2026-04-06T14:48:50.490249+00:00Z",
    "trace_id": "fa2af438-fd7f-48b6-a5df-1af51118af54"
  },
  "service": {
    "github": "https://github.com/vanallenlab/moalmanac-db",
    "name": "Molecular Oncology Almanac",
    "license": "GPL-2.0",
    "release": "draft",
    "url": "https://dev.moalmanac.org",
    "last_updated": "2026-03-05"
  },
  "data": [
    {
      "id": "ind:hc.revlimid:0",
      "indication": "REVLIMID (lenalidomide) is indicated for the treatment of patients with transfusion-dependent anemia due to Low- or Intermediate-1-risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. Approval for this indication is based on red blood cell transfusion independence response rates. Overall survival benefit has not been demonstrated.",
      "initial_approval_date": null,
      "initial_approval_url": null,
      "description": "Health Canada approved lenalidomide for the treatment of patients with transfusion-dependent anemia due to Low- or Intermediate-1-risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogentic abnormalities.",
      "raw_biomarkers": "5q deletion",
      "raw_cancer_type": "transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes",
      "raw_therapeutics": "Revlimid (lenalidomide)",
      "icd10": null,
      "regimen_code": null,
      "reimbursement_category": null,
      "reimbursement_date": null,
      "reimbursement_details": null,
      "date_regular_approval": null,
      "date_accelerated_approval": null,
      "document": {
        "id": "doc:hc.revlimid",
        "type": "Document",
        "documentType": "Regulatory approval",
        "name": "Revlimid (lenalidomide) [product monograph]. HC.",
        "title": null,
        "aliases": [],
        "description": "Bristol-Myers Squibb Canada. Revlimid (lenalidomide) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00074535.PDF. Published February 2024. Accessed June 2025.",
        "urls": [
          "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79016",
          "https://pdf.hres.ca/dpd_pm/00074535.PDF"
        ],
        "doi": null,
        "pmid": null,
        "extensions": [
          {
            "name": "agent",
            "value": {
              "id": "hc",
              "type": "Agent",
              "agentType": "organization",
              "name": "Health Canada",
              "description": "Regulatory agency that approves drugs for sale and use in Canada.",
              "extensions": [
                {
                  "name": "last_updated",
                  "value": "2025-06-11",
                  "description": ""
                },
                {
                  "name": "url",
                  "value": "https://health-products.canada.ca/dpd-bdpp/",
                  "description": ""
                }
              ]
            },
            "description": "The organization that published this document."
          },
          {
            "name": "company",
            "value": "Bristol-Myers Squibb Canada",
            "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
          },
          {
            "name": "drug_name_brand",
            "value": "Revlimid",
            "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
          },
          {
            "name": "drug_name_generic",
            "value": "lenalidomide",
            "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
          },
          {
            "name": "first_publication_date",
            "value": "2024-02-09",
            "description": "The publication date for the initial version of this document."
          },
          {
            "name": "identification_number",
            "value": null,
            "description": "Identification number used by the publishing organization."
          },
          {
            "name": "publication_date",
            "value": "2024-02-09",
            "description": "The publication date for the document."
          },
          {
            "name": "status",
            "value": "Active",
            "description": "Whether this document is Active or Deprecated within moalmanac-db."
          }
        ]
      }
    }
  ]
}